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Abstract: Polyphenols compounds are a group molecules present in many plants. They have
antioxidant properties and can also be helpful in the management of sepsis. Licochalcone C (LicoC), a
constituent of Glycyrrhiza glabra, has various biological and pharmacological properties. In saying this,
the effect of LicoC on the inflammatory response that characterizes septic myocardial dysfunction is
poorly understood. The aim of this study was to determine whether LicoC exhibits anti-inflammatory
properties on H9c2 cells that are stimulated with lipopolysaccharide. Our results have shown
that LicoC treatment represses nuclear factor-κB (NF-κB) translocation and several downstream
molecules, such as inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Moreover, LicoC has upregulated the
phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/endothelial nitric oxide synthase (eNOS)
signaling pathway. Finally, 2-(4-Morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride
(LY294002), a specific PI3K inhibitor, blocked the protective effects of LicoC. These findings indicate
that LicoC plays a pivotal role in cardiac dysfunction in sepsis-induced inflammation.
Keywords: inflammation; nitric oxide; licochalcone C; adhesion molecule; cardiomyocytes; nuclear
factor-κB; Akt
1. Introduction
Sepsis is a final common pathway to death from infection. It is characterized by a systemic
inflammatory disorder, which leads to multiorgan failure with immune dysfunction [1]. Septic cardiac
dysfunction, caused by bacterial endotoxin lipopolysaccharide (LPS), clearly manifests severe sepsis,
making it the predominant cause of death in patients with sepsis [2,3]. Existing studies have shown
that the mitigation of cardiac dysfunction in sepsis could improve the outcomes of patients with sepsis.
Considering this evidence, treatments for sepsis with anti-inflammatory drugs have demonstrated a
decreased risk of cardiovascular complications [4,5]. Nuclear factor kappa B (NF-κB) is an important
transcription factor, as it activates several inflammatory genes after immune-stimulation. Generally, in
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unstimulated cells, NF-κB is retained in the cytoplasm bound with the inhibitor of NF-κB protein (IκB).
Exposure to LPS leads to the activation of the IκB kinase (IKK) complex, inducing phosphorylation and
subsequent degradation of IκB. Therefore, NF-κB is liberated and is subsequently translocated into the
nucleus where it binds to DNA-response elements [6,7]. In septic cardiac dysfunction, the activation
of these signaling cascades has been implicated in the release of genes activated by NF-κB, such as
inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1) and vascular cell
adhesion molecule-1 (VCAM-1) [8]. These molecules are present in elevated quantities in patients
with an inflammatory state, such as sepsis, and may have detrimental effects on cardiomyocytes,
leading to sepsis-associated myocardial dysfunction [9]. In this context, the activity of iNOS leads
to excessive NO production that causes decreased vascular tonus and consequently hypotension,
which is a characteristic of this syndrome. Instead, ICAM-1 and VCAM-1 are localized in the cell
membrane of both the cells covering the vascular endothelium and leukocytes and are involved in
the migration into adjacent tissues to inflammatory cells. Several experimental data evidenced that
the inhibition of iNOS could be an important therapeutic target to treat septic shock patients and
that the adhesion molecules (ICAM-1 and VCAM-1) have been relate with the gravity of the sepsis
syndrome [10–12]. The phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) pathway plays an
important role in many biological responses, including inflammatory reactions, chemotaxis, cellular
activation and apoptosis. It also regulates inflammatory genes. A number of studies have shown
that sepsis reduces myocardial PI3K/Akt signaling pathway activation [13,14]. The major signaling
molecule of PI3K is Akt, an upstream enzyme of endothelial nitric oxide synthase (eNOS), unlike
iNOS, which is responsible for the production of physiological amounts of nitric oxide (NO). The
PI3K-Akt pathway has different effects on NF-κB and in turn on the expression of inflammatory
molecules. Recent studies have highlighted that in HepG2 cells and in human monocytic cells, the
PI3K-Akt pathway increases nuclear translocation of p65 [15,16]. Studies have also shown that in
fibroblasts, an overexpression of Akt increases NF-κB-dependent gene expression [17]. In contrast, in
regards to macrophages, C6 glioma cells and rat primary astrocytes activation of PI3K-Akt represses
LPS-induced iNOS [18]. Over recent years, an increasing number of studies have suggested that
several dietary compounds produce a variety of phytochemical compounds, such as polyphenols
and flavonoids. These compounds have ample biological activities and can reduce the risk of disease.
They also have a therapeutic potential on the cardiovascular system and have antihypertensive and
anti-atherosclerotic effects [19–21]. Chalcones are a group of plant-derived polyphenolic compounds
belonging to the flavonoids family and are characterized by a variety of cytoprotective functions due to
their antioxidant activity. [22,23]. Firstly, we extracted Licochalcone C (LicoC) from Glycyrrhiza glabra,
which was shown to decrease the inflammatory response in a monocytic cell line. This showed
a reduction in iNOS expression and activity and a restoration in the antioxidant network activity
of superoxide dismutase, catalase and glutathione peroxidase [24]. Moreover, recently, it has been
reported that the cardioprotective effect of LicoC in myocardial ischemia/reperfusion injury may lead
to antioxidant, anti-inflammatory and anti-apoptotic activities [25]. However, little is known on the
molecular mechanisms of LicoC in cardiac cells. In this study, we investigated in vitro effects of LicoC
on H9c2 cells protection and to elucidate its underlying mechanisms.
2. Results
2.1. Licochalcone C (LicoC) Does Not Affect the Viability of and Alleviated Lipopolysaccharide (LPS)-Induced
Cytotoxicity in H9c2 Cells
In this study, the effects of LicoC on cell viability in a model of a cardiomyocyte cell line, H9c2,
were first investigated by the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay.
When cells were treated with LicoC, ranging from 1–500 µM for 48 h, cell viability did not change
significantly with respect to the control up to 250 µM (Figure 1A). Subsequently, we evaluated the
effect of LicoC on LPS-induced inflammation. It was found that LPS treatment for 24 h caused about
55.04% ± 9.78% of cell death (Figure 1B). However, pretreatment with LicoC significantly protected
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cells from insults induced by LPS in a concentration-dependent manner. Statistically, a significant
inhibition effect on the cytotoxicity of LicoC commenced at 25 µM. As LPS quickly stimulated reactive
oxygen species (ROS) generation, to assess whether LicoC reduces LPS-induced ROS production in
H9c2 cells, cells were co-treated with LicoC (1–250 µM) or/and LPS. Furthermore, the level of ROS
reflected by the nitro blue-tetrazolium (NBT) assay was evaluated. As expected, the ROS level was
much higher in the cardiomyocytes stimulated with LPS with respect to control cells, while as cells
are incubated with LicoC, we observed a significant reduction of ROS production (Figure 1C). LicoC
significantly reduced the LPS-induced ROS generation at concentrations greater than 10 µM, indicating
that LicoC was able to reduce intracellular ROS accumulation after LPS stimulation. Thus, LicoC at
25 µM was more often used in the following experiments to test the role of this natural compound
against LPS-induced effects.
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Figure 1. Effects of licochalcone C (LicoC) and/or Lipopolysaccharide (LPS) on H9c2 cells’ viability 
and toxicity. (A) Cell viability was measured by the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide (MTT) assay, incubating H9c2 cells with increasing concentrations of LicoC (0–500 µM) for 
24 h. Cell viability was not significantly affected by any tested LicoC concentrations; (B) LPS 
decreased the viability of H9c2 cells, but treatment with LicoC at concentrations greater than 10 µM 
restores cell viability; (C) Cells were treated with LicoC (1–250 µM) and LPS for 24 h. Reactive Oxygen 
Species (ROS) production was measured by the nitro blue-tetrazolium (NBT) assay. # p < 0.05 vs. 
control cells; ∗ p < 0.05 vs. LPS. 
2.2. Effect of LicoC on Nuclear Factor Kappa B (NF-κB)/Inducible Nitric Oxide Sinthase (iNOS)/Nitric 
Oxide (NO) Pathway 
The nuclear translocation of NF-κB p65 was assessed by Western blot analysis to verify the anti-
inflammatory effects of LicoC on H9c2. As shown in Figure 2A, LPS producesa nuclear translocation 
of p65 in H9c2 cells. However, the pre-treatment with LicoC blocks the nuclear translocation of NF-
κB p65 from the cytosol. Thus, we analyzed if the LicoC effect on NF-κB nuclear translocation was 
associated with the IκB phosphorylation. The activation of H9c2 cells with LPS leads to Iκ-Bα 
phosphorylation, allowing for the relocation of NF-κB to the nucleus. Pretreatment with our 
compound blocked Iκ-Bα phosphorylation, preventing p65 nuclear translocation induced by LPS 
(Figure 2B). We found that LicoC decreases LPS-induced inflammatory responses in H9c2 cells by 
blocking the activation of the transcription factor NF-κB. We then assessed the effect of LicoC on 
iNOS/NO signaling. Protein analysis demonstrated a higher expression of iNOS in activated cells 
compared to control cells, whilst LicoC-treated cells significantly decreased it (Figure 2C). This 
upregulation of iNOS expression is also associated with an increased enzyme activity, as seen in the 
analysis of culture medium levels of NO by using the Griess assay. Compared to the medium-control, 
LPS on its own significantly increased NO levels, whilst LicoC at a concentration of 25 µM markedly 
reduced the production of NO in LPS-activated cells, in comparison to control cells (Figure 2D). 
Figure 1. Effects of licochalcone C (LicoC) and/or Lipopolysaccharide (LPS) on H9c2 cells’ viability and
toxicity. (A) Cell viability was measured by the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium
bromide (MTT) assay, incubating H9c2 cells with increasing concentrations of LicoC (0–500 µM) for
24 h. Cell viability was not significantly affected by any tested LicoC concentrations; (B) LPS decreased
the viability of H9c2 cells, but treatment with LicoC at concentrations greater than 10 µM restores cell
viabili y; (C) Cells were treated with LicoC (1–250 µM) and LPS for 24 h. Reactive Oxyg n Species
(ROS) product on was mea ured by the nitro blue-tetrazolium (NBT) assay. # p < 0.05 vs. con rol cells;
∗ p < 0.05 vs. LPS.
2.2. Effect of LicoC on Nuclear Factor Kappa B (NF-κB)/Inducible Nitric Oxide Sinthase (iNOS)/Nitric Oxide
(NO) Pathway
The nuclear translocation of NF-κB p65 was assessed by Western blot analysis to verify the
anti-inflammatory effects of LicoC on H9c2. As shown in Figure 2A, LPS producesa nuclear
translocation of p65 in H9c2 cells. However, the pre-treatment with LicoC blocks the nuclear
translocation of NF-κB p65 from the cytosol. Thus, we analyzed if the LicoC effect on NF-κB nuclear
tra slocation was associated with the IκB phosphorylation. The activation of H9c2 cells with LPS
leads to Iκ-Bα phosphorylation, allowing for the relocation of NF-κB to the nucleus. Pretreatme t
wi h our compound blocked Iκ-Bα ph sphorylation, preventing p65 nuclear translocation induced
by LPS (Figure 2B). We found that LicoC decreases LPS-induced inflammatory responses in H9c2
cells by blocking the activation of the transcription factor NF-κB. We then assessed the effect of LicoC
on iNOS/NO signaling. Protein analysis demonstrated a higher expression of iNOS in activated
cells compared to control cells, whilst LicoC-treated cells significantly decreased it (Figure 2C). This
upregulation of iNOS expression is also associated with an increased enzyme activity, as seen in the
analysis of culture medium levels of NO by using the Griess assay. Compared to the medium-control,
LPS on its own significantly increased NO levels, whilst LicoC at a concentration of 25 µM markedly
reduced the production of NO in LPS-activated cells, in comparison to control cells (Figure 2D).
Int. J. Mol. Sci. 2017, 18, 690 5 of 14
Int. J. Mol. Sci. 2017, 18, 690  5 of 14 
 
 
Figure 2. Effect of LicoC on NFκB/iNOS/NO signaling in LPS-stimulated H9c2 cells. Cells were 
pretreated with LicoC (25 µM) for 30 min and were then stimulated with LPS (10 µg/mL) for 24 h. 
After the indicated time, cells were harvested and lysed. Western blot analysis, in the absence (−) or 
presence (+) of LicoC or LPS, was used to investigate p-p65 NF-κB nuclear protein (A), as well as to 
detect the cellular expression of pIKBα (B) and iNOS (C). Equal loading was verified using an un-
phosphorylated isoform and an anti-β-actin antibody. Densitometric analysis was carried out using 
Bio-Rad Quantity One Analysis software. Each column represents the mean ± SD of three independent 
experiments; (D) Effects of LicoC on NO levels in H9c2 cells stimulated by LPS. NO levels were 
quantified by the accumulation of nitrite in the cell culture medium and are expressed as µmol·L−1/106 
cells. Data are expressed as the mean ± SD of different experiments performed in triplicate; * p <0.05 
vs. LPS-treated cells; # p < 0.05 vs. control cells. Data were analyzed by one-way ANOVA followed by 
Bonferroni’s test. 
2.3. LicoC Elevated PI3-K/Akt/eNOS Pathways 
To strengthen our hypothesis about the protective mechanism of LicoC on cardiomyocyte cells, 
expressions of PI3-K/Akt signaling molecules were determined through Western blotting analysis. 
The analysis for phospho-specific and active isoforms of PI3-K and Akt was performed on 
homogenate cells subjected to pro-inflammatory stimulus and/or LicoC. As shown in Figures 3A and 
3B, the densitometric analysis of phospho-PI3K and phospho-Akt demonstrated that in cells 
subjected to stress, there was a decrease in PI3K and Akt phosphorylation compared to control cells. 
It has been shown that phosphorylation of Akt is an important cellular signaling event for eNOS 
activation, resulting in the protection of cardiomyocytes [26]. Therefore, to further determine the 
underlying mechanism of the effects of LicoC on H9c2 cells, we tested the expression of eNOS using 
a specific antibody. Western blot analysis of eNOS protein demonstrated the reduction of a band in 
the cell activated with LPS (Figure 3C). When we treat the cells with LicoC, we saw both an increase 
in phosphorylation levels of eNOS and an increase in pAkt and pPI3K expressions. No changes in β-
actin expression were evident between the control cells, nor the LPS-LicoC-incubated cells. 
Figure 2. Effect of LicoC on NFκB/iNOS/NO signaling in LPS-stimulated H9c2 cells. Cells were
pretreated with LicoC (25 µM) for 30 min and were then stimulated with LPS (10 µg/mL) for 24 h. After
the indicated time, cells were harvested and lysed. Western blot analysis, in the absence (−) or presence
(+) of LicoC or LPS, was used to investigate p-p65 NF-κB nuclear protein (A), as well as to detect the
cellular expression of pIKBα (B) and iNOS (C). Equal loading was verified using an un-phosphorylated
isoform and an anti-β-actin antibody. Densitometric analysis was carried out using Bio-Rad Quantity
One Analysis software. Each column represents the mean ± SD of three independent experiments;
(D) Effects of LicoC on NO levels in H9c2 cells stimulated by LPS. NO levels were quantified by the
accumulation of nitrite in the cell culture medium and ar expressed as µmol·L−1/106 cells. Data are
expressed as th mean ± SD of different experiments performed i tri licate; * p < 0.05 vs. LPS-treated
cells; # p < 0.05 vs. control cells. Data were analyzed by one-w y ANOVA followed by Bonferroni’s test.
2.3. LicoC Elevated PI3-K/Akt/eNOS Pathways
To strengthen our hypothesis about the protective mechanism of LicoC on cardiomyocyte cells,
expressions of PI3-K/Akt signaling molecules were determined through Western blotting analysis. The
analysis for phospho-specific and active isoforms of PI3-K and Akt was performed on homogenate cells
subjected to pro-inflammatory stimulus and/or LicoC. As shown in Figure 3A,B, the densitometric
analysis of phospho-PI3K and phospho-Akt demonstrated that in cells subjected to stress, there
was a decrease in PI3K and Akt phosphorylation compared to control cells. It has been shown that
phosphorylation of Akt is an important cellular signaling event for eNOS activation, resulting in the
protection of cardiomyocytes [26]. Therefore, to further determine the underlying mechanism of the
effects of LicoC on H9c2 cells, we tested the expression of eNOS using a specific antibody. Western
blot analysis of eNOS protein demonstrated the reduction of a band in the cell activated with LPS
(Figure 3C). When we treat the cells with LicoC, we saw both an increase in phosphorylation levels of
eNOS and an increase in pAkt and pPI3K expressions. No changes in β-actin expression were evident
between the control cells, nor the LPS-LicoC-incubated cells.
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2.4. LicoC Inhibits Intercellular Adhesion Molecule 1 (ICAM-1) and Vascular Cell Adhesion
Protein 1 (VCAM-1)
To further understand the cardio-protective role of LicoC and to assess the potential signaling
pathways contributing to the properties of this natural compound, we analyzed the expression of
adhesion molecules VCAM-1 and ICAM-1 in H9c2 cells after LPS stimulation. Figure 4 shows that LPS
stimulation induces a significant upregulation of the expression of VCAM-1 and ICAM-1 compared to
control cells (p < 0.01). However, treatment with LicoC leads to a marked reduction of VCAM-1 and
ICAM-1 levels by 20.4% and 34.0%, respectively, in LPS-stimulated cells when compared to activated
cells that were not treated with LicoC (p < 0.01). These data suggest that LicoC acts on cardiomyocytes
to produce an anti-inflammatory effect.
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2.5. Involvement of PI3K on the Protective Effect of LicoC on LPS-Induced H9c2 Inflammation
To investigate the role of PI3K/Akt signaling activation on the cardio-protective effect of LicoC
against LPS-induced inflammation, we pre-treated cells with a selective PI3K inhibitor LY294002
(2-(4-Morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride). As shown in Figure 5A,
LY294002 blocks the preserved activation of the eNOS induced by LicoC in LPS stimulated cells. We
then studied whether the inhibition of PI3K/Akt/eNOS signaling with LY294002 modified the iNOS
activity and the protein expression of adhesion molecules ICAM-1 and VCAM-1. Our experimental
analysis showed that the LicoC-induced reduction of ICAM-1 and VCAM-1 proteins expression
and iNOS activity was blocked by the treatment of cells with the PI3K-specific inhibitor LY294002,
demonstrating that they need PI3-K/Akt activation. LY294002 eliminated the protective effect of LicoC
on the attenuation of cellular homeostasis alteration in LPS-induced sepsis. These data highlight that
LicoC exerts its effect by activating the PI3K/Akt signaling pathway.
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Figure 5. Effect of LicoC on adhesion molecules and on NOS activity in H9c2 cells treated with LPS,
LicoC, 2-(4-Morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride (LY294002) or all (LPS,
LicoC, LY294002). Cells were pretreated with LicoC (25 µM) and LY294002 (10 µM) for 30 and 60 min
respectively before stimulation with LPS (10 µg/mL) for 24 h. VCAM-1 and ICAM-1 protein expression
was normalized to β actin (A); eNOS and iNOS activity (B) values are expressed as the means ± SD of
three experiments. * p < 0.05 vs. LPS + LicoC.
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3. Discussion
Sepsis is a serious clinical problem related to a poor prognosis characterized by severe systemic
inflammatory response to infection, possibly leading to cardiac dysfunction. This study aimed to
investigate the mechanisms responsible for the putative protective effect of LicoC on cultured H9c2
cardiomyocytes. It has been shown that this cell line exhibits a marked inflammatory response to
LPS stimulation. Thus, the H9c2 cell line is a sufficient model to study the therapeutic potential
of molecules for the treatment of cardiac dysfunction induced by sepsis [27]. Firstly, we found
that in cardiomyocytes, LicoC does not reduce viability, but does exhibit significant attenuation of
LPS-induced toxicity in the H9c2 cell line (Figure 1A,B). Oxidative stress, a condition caused by
excessive production of free radicals, plays an important role in the progression of an inflammatory
condition [28,29]. LPS, released from the surface of the cell membrane of Gram-negative bacteria,
triggers an inflammatory response and causes severe sepsis. The cellular response to LPS includes the
production of ROS and other mediators, such as NO and pro-inflammatory cytokines [30,31]. Therefore,
we studied the possibility of LicoC in decreasing the cellular accumulation of ROS LPS-induced. As
shown in Figure 1C, LicoC has a significant decrease in ROS production on H9c2 cells activated with
LPS. To demonstrate how LicoC plays a role in the inflammation process, we analyzed its effects on
H9c2 cells. H9c2 cells exposed to LPS show an increased activation of NF-κB. The transcription factor
NF-κB plays an important role in LPS-induced transcriptional regulation, controlling various target
inflammatory genes, such as acute phase proteins, cell adhesion molecules, cytokines and chemokines
and stress-responsive genes [32,33]. As shown in Figure 2A,B, treatment with LicoC, inhibited Iκ-Bα
phosphorylation, prevents the nuclear translocation of p65 and increases the expression and activity
of iNOS induced by LPS. These data suggest that the biological effect exerted by LicoC towards
LPS-induced cardiac inflammation was associated with the inhibition of nuclear translocation of NF-κB.
As many studies have demonstrated that in some cell lines, PI3K/Akt activation negatively regulates
the NF-κB activation pathway, limiting pro-inflammatory responses, improving cardiac function in
septic mice [34–36], we have examined whether the inhibition of NF-κB activation by LicoC is mediated
via the PI3K/Akt pathway. PI3K/Akt signaling is an important pathway involved in controlling
cardiomyocytes function and survival. It has been previously shown that one of the downstream
effectors of Akt in the PI3K/Akt pathway is eNOS, which after phosphorylation, leads to the production
of NO [37,38]. Endothelial-derived NO acts as a protective agent in a variety of diseases. It plays
a pivotal role in the cardiovascular system as a key secondary messenger in the signaling pathway
through the regulation of physiological activities, such as regional vascular tone; the maintenance of
vascular integrity and leukocyte adhesion to the endothelium, as well as angiogenesis [39]. Our results
show that the biological effects of LicoC are linked to the PI3K/Akt/eNOS pathway by promoting
the phosphorylation of these proteins (Figure 3). Constitutively expressed eNOS has favorable
effects on cellular function, while iNOS has adverse effects on cells mostly under conditions of stress,
including sepsis. In our previous study, we observed that, in H9c2 cells, LPS markedly decreased iNOS
expression and increased eNOS expression, suggesting the presence of an imbalance between iNOS
and eNOS after LPS stimulation [3]. During sepsis, this imbalance could contribute to alteration of
microvascular tone and integrity, as well as the activation of cell adhesion molecules, such as VCAM-1
and ICAM-1. Interestingly, LicoC pre-treatment significantly abrogated the downregulation of eNOS
and the upregulation of iNOS (Figure 3B,C). This suggests that the cardioprotective effect of LicoC
against LPS stimulation could be related to the maintenance of the balance between the constitutive
and inducible isoforms of NOS during inflammation. Findings from previous studies have shown that
in addition to iNOS, VCAM-1 and ICAM-1 are also inflammatory molecules primarily activated by
NF-κB [40]. Elevated expression of adhesion molecules, such as VCAM-1 and ICAM-1, appears to be
important in the controlling of lymphocyte migration from the vasculature into the myocardium, which
in turn leads to the reduction of left ventricular contractility after the triggering of an inflammatory
process [41]. In accordance with this experimental evidence, we observed that in LPS-activated H9c2
cells, the expression levels of adhesion molecules, VCAM-1 and ICAM-1, have significantly increased.
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We can see that the upregulation of ICAM-1 and VCAM-1 by LPS has been effectively abrogated by
LicoC treatment (Figure 4). This shows that LicoC reduces inflammation in LPS-activated cells. Finally,
inhibition of PI3K/Akt signaling by LY294002 repressed the LicoC-induced cellular protection during
endotoxemia, which resulted in the increased activity, as well as the expression of molecules related to
inflammation, such as iNOS, VCAM-1 and ICAM-1, regulated by transcription factor NF-κB (Figure 5).
Moreover, we noticed a reduction in the activity of a key molecular implicated in the maintenance
of endothelial function, eNOS protein. These results suggest a direct involvement of the PI3K/Akt
pathway in LicoC-induced NF-κB deactivation.
4. Materials and Methods
4.1. Cell Culture
H9c2 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA,
USA). Cells were cultured in a 5% CO2 atmosphere in DMEM with 10% Fetal Bovine Serum (FBS),
100 ng/mL streptomycin, 100 U/mL penicillin and 2 mM L-glutamine. Then, 2 × 105 cells were
seeded onto culture plates and cultured in medium with Lipopolysaccharide (LPS) (10 µg/mL) for
24 h, with or without LicoC and/or LY294002, 10 µM, Sigma-Aldrich, St. Louis, MO, USA, Catalog
Number L9908). LicoC and PI3K inhibitor LY294002 were added to the culture medium 30 and 60 min,
respectively, before the LPS treatment. After incubation time, cells were collected for analysis of cellular
viability, gene and protein expression. Culture medium was retained to estimate the NO level.
4.2. 3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium Bromide (MTT) Assay for Cell Viability
and Cytotoxicity
To assess the cell viability and toxicity of LicoC, the MTT assay was used, which was performed
as described above [42]. Briefly, the cells were seeded on 96-well plates (8 × 103 cells/well), and
the reagent MTT at a concentration of 0.5 mg/mL (20 µL) and medium (200 µL) were added to each
well. The plates were incubated at 37 ◦C (4 h). Then, the solution (220 µL) was removed, and DMSO
(150 µL) was added. The reading of the amount of reduced MTT was measured on an ELISA reader
(Bio-Rad, Hercules, CA, USA) at 570 nm. The following equation was used to calculate the percentage
of cell viability:
% = (Absorbance of treated cells)/(Absorbance of control cells) × 100
4.3. Nitro Blue-Tetrazolium Assay
Superoxide anion production was monitored using the nitro blue-tetrazolium (NBT) assay.
As described previously [43], to each well were added: 100 µL PBS (pH 7.8, 50 mM), 5 µL catalase,
25 µL NBT (5.6 × 10−9 M), 50 µL xanthine (0.1 mM), 50 µL xanthine oxidase (0.1 mM) and LicoC
(1–250 µM). Following the addition of NBT, the plates were incubated at RT for 1 h, and the amount of
NBT formazan was quantified at 560 nm.
4.4. Western Blot Analysis
For Western blot analysis, the cells were harvested with RIPA lysis buffer as described
previously [44]. Nuclear extracts were prepared as described above [45]. The Bradford Method
was used for protein quantification. Western Blot analysis was performed as described previously [46]
incubating the membrane with antibodies against IKB, pIκB, p65-NFκB, p-p65-NFκB, VCAM-1 and
ICAM-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (dilution 1:500). β-actin was used as a
protein loading control.
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4.5. Griess Assay
The assay was performed as described above [3]. Briefly, the cells were seeded, and nitrite
was measured in culture medium supernatants as an indicator of the NO levels. To assess nitrite
concentration, sodium nitrite was used as a standard. Aliquots of the culture supernatant were mixed
with an identical volume of the Griess reagent, and absorbance was detected spectrophotometrically at
540 nm.
4.6. Nitric Oxide Sinthase (NOS) Activity
The oxyhemoglobin assay was performed to detect nitric oxide formation from NOS as
described above [47]. The reaction mixture for the evaluation of NOS activity was constituted
by CaCl2 (1.6 mM), L-arginine (10 µM), calmodulin (11.6 mg/mL), tetrahydrobiopterin (6.5 µM),
dihydronicotinamide-adenine dinucleotide phosphate (NADPH, 100 µM) and oxyhemoglobin (3 mM)
in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 100 mM) (pH 7.5) in a final volume of
1 mL. iNOS activity was performed in calcium-free conditions. The quantization of methemoglobin
as the product of the reaction between nitric oxide and oxyhemoglobin was detected at 576 nm
(e = 12.000 M−1·cm−1) using a Perkin-Elmer LamdaBIO UV-Vis spectrophotometer (Perkin-Elmer,
Milano, Italy).
4.7. Statistical Analysis
All results are reported as the means ± SD. To show the difference between samples, considered
as statistically significant.
5. Conclusions
Our study demonstrates a new mechanism of action through which LicoC positively modulates
the functional recovery and integrity of endothelial function. This occurs through the controlling of
both NO concentration and expression of adhesion molecules. Therefore, LicoC may be used as an
adjuvant treatment in order to reduce cardiomyocyte inflammation.
Provided that the cardioprotective effect is mediated by LicoC in vitro through the negative
modulation of closely-related molecules to inflammatory etiopathogenesis, it would be desirable to
undertake a further study of an evaluation of the same pathways (PI3K/Akt/eNOS) in vivo.
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